LOW-DOSE MELPHALAN FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

Citation
E. Omoto et al., LOW-DOSE MELPHALAN FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES, Leukemia, 10(4), 1996, pp. 609-614
Citations number
33
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Hematology,Oncology
Journal title
ISSN journal
0887-6924
Volume
10
Issue
4
Year of publication
1996
Pages
609 - 614
Database
ISI
SICI code
0887-6924(1996)10:4<609:LMFTOH>2.0.ZU;2-4
Abstract
Twenty-one consecutive patients with high-risk myelodysplastic syndrom es (MDS) including six with refractory anemia with excess blasts (RAEB ) and 15 with RAEB in transformation (RAEBt) were treated with daily o ral low-dose melphalan (2 mg/day). Seven patients achieved complete re mission (CR), one patient partial response, and four minor response wh ile the remaining eight did not respond. The median age of the patient s was 65 (range 56-83 years). The mean total amount of melphalan given was 140 +/- 19 mg in patients who achieved CR. The median duration of CR was 14.5 months. Serious toxicity was not encountered in any of th e cases. Neither marrow suppression nor pancytopenia was observed duri ng the administration of melphalan in patients who achieved CR. The cl inical features of CR patients included normal karyotype and hypocellu lar marrow in biopsied specimen from the iliac bone. These observation s suggest that melphalan may exert some differentiation effects on leu kemic cells in addition to cytotoxic effects. Our study indicates that daily administration of low-dose melphalan is worth trying in the tre atment of elderly patients with high-risk MDS.